* Myriad Genetics Inc MYGN.OQ reported quarterly adjusted
earnings of 6 cents per share for the quarter ended September
30, higher than the same quarter last year, when the company
reported EPS of -3 cents. The mean expectation of
fifteen analysts for the quarter was for earnings of 2 cents per
share. Wall Street expected results to range from zero cents
to 5 cents per share.
* Revenue rose 11.2% to $213.30 million from a year ago;
analysts
expected $210.73 million.
* Myriad Genetics Inc's reported EPS for the quarter was a
loss
of 24 cents.
* The company reported a quarterly loss of $22.1 million.
* Myriad Genetics Inc shares had fallen by 35.9% this
quarter and
lost 8.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 23.4%
in the last three months.
* In the last 30 days, two analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 4
"hold" and 4 "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "hold"
Wall Street's median 12-month price target for Myriad Genetics
Inc is 30.00
This summary was machine generated from LSEG data November 8 at
04:41 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.02 0.06 Beat
Jun. 30 2024 -0.01 0.05 Beat
Mar. 31 2024 -0.10 -0.01 Beat
Dec. 31 2023 0.01 0.04 Beat